For advanced breast cancer patients receiving aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, monitoring the emergence of estrogen receptor 1 (ESR1) mutations holds potential clinical utility. Here, ESR1 is linked to breast carcinoma.